Disease modifying trials in Alzheimer disease: methodological and statistical issues

Area of Science:

• Clinical pharmacology
• Drug development
• Biostatistics

Background:

• Assessing drug efficacy requires evaluating both symptomatic relief and disease modification.
• Disease-modifying treatments aim to alter the underlying disease process, not just symptoms.

Purpose of the Study:

• To highlight the methodological considerations in designing clinical trials for disease-modifying drugs.
• To discuss key decisions in trial design, outcome selection, and statistical analysis.

Main Methods:

• Review of methodological issues in clinical trial design for disease modification.
• Discussion of parallel arm versus two-period designs.
• Consideration of clinical versus surrogate outcomes and statistical analysis, including handling missing data.

Main Results:

• Disease-modifying trials necessitate careful consideration of study design.
• The choice between parallel arm and two-period designs impacts trial interpretation.
• Selecting appropriate outcomes (clinical vs. surrogate) and statistical methods for missing data is crucial.

Conclusions:

• Effective clinical trials for disease modification require robust methodological planning.
• Addressing design, outcome, and statistical challenges is essential for accurate assessment of drug impact.
• Methodological rigor ensures reliable evidence for disease-modifying drug efficacy.